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Background: A subset of CD3negCD56negCD16+ Natural Killer (NK) cells is highly expanded during chronic HIV-1
infection. The role of this subset in HIV-1 pathogenesis remains unclear. The lack of NK cell lineage-specific markers
has complicated the study of minor NK cell subpopulations.
Results: Using CD7 as an additional NK cell marker, we found that CD3negCD56negCD16+ cells are a heterogeneous
population comprised of CD7+ NK cells and CD7neg non-classical myeloid cells. CD7+CD56negCD16+ NK cells are
significantly expanded in HIV-1 infection. CD7+CD56negCD16+ NK cells are mature and express KIRs, the C-type
lectin-like receptors NKG2A and NKG2C, and natural cytotoxicity receptors similar to CD7+CD56+CD16+ NK cells.
CD7+CD56neg NK cells in healthy donors produced minimal IFNγ following K562 target cell or IL-12 plus IL-18
stimulation; however, they degranulated in response to K562 stimulation similar to CD7+CD56+ NK cells. HIV-1
infection resulted in reduced IFNγ secretion following K562 or cytokine stimulation by both NK cell subsets
compared to healthy donors. Decreased granzyme B and perforin expression and increased expression of CD107a
in the absence of stimulation, particularly in HIV-1-infected subjects, suggest that CD7+CD56negCD16+ NK cells may
have recently engaged target cells. Furthermore, CD7+CD56negCD16+ NK cells have significantly increased
expression of CD95, a marker of NK cell activation.
Conclusions: Taken together, CD7+CD56negCD16+ NK cells are activated, mature NK cells that may have recently
engaged target cells.
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CD56neg NK cellsBackground
Natural killer (NK) cells comprise 5–20% of peripheral
blood mononuclear cells (PBMC) in humans and play a
fundamental role in the defense against viral infections,
as well as in tumor surveillance, and help shape adaptive
immune responses through their production of cytokines
[1-3]. NK cells are traditionally identified as CD3neg,
CD14neg, CD19neg lymphocytes expressing CD56 (neural
cell adhesion molecule) and NKp46 [4], although not all
human NK cells express NKp46 [1]. NK cells are* Correspondence: Jeffrey.Milush@ucsf.edu
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reproduction in any medium, provided the ortypically characterized into two main subsets;
CD56dimCD16+ NK cells, which comprise approximately
90% of circulating NK cells and are considered mature,
and CD56brightCD16neg/dim NK cells, which represent ap-
proximately 10% and are considered immature [1,5]. A di-
verse array of activating and inhibitory receptors controls
their function. Upon activation, NK cells secrete IFNγ and
other cytokines and kill susceptible target cells [2].
Initial studies of NK cells during Human Immunodefi-
ciency Virus (HIV-1) infection found significantly reduced
absolute numbers of CD3negCD56+CD16+ NK cells with a
concomitant increase in CD3negCD56negCD16+ cells [6-8].
In HIV-1-infected subjects, CD3negCD56negCD16+ cells
are described as having decreased expression of activatingLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of inhibitory receptors (i.e. LIR-1 and inhibitory KIR), and
have poor cytolytic, proliferative, and cytokine-producing
capabilities [8-14]. It has been hypothesized that the expan-
sion of this defective CD3negCD56negCD16+ population
might be one mechanism by which HIV-1 subverts the NK
cell response.
Expansion of CD3negCD56negCD16+ cells has also been
observed in other infectious diseases (i.e. hantavirus and
chronic hepatitis C virus (HCV) infection) [15,16], as well
as in ocular myasthenia gravis [17] and dermatomyositis
[18]. Common to each of these pathological conditions is
immune activation. Indeed, chronic immune activation is
a hallmark of untreated HIV-1 disease and results in accel-
erated immunosenescence [19]. In healthy subjects, one
study has suggested that NK cells might proliferate and
die more rapidly than do T cells however this requires fur-
ther investigation [20]. We recently demonstrated that
CD57 is a marker of terminally differentiated NK cells
[21], and that during acute cytomegalovirus (CMV) infec-
tion NKG2Chi-expressing NK cells acquire expression of
CD57 [22]. Importantly, treatment with antiviral drugs in
HIV-1 and HCV infection or immunosuppressants for
myasthenia gravis and dermatomyositis decrease the fre-
quency of CD3negCD56negCD16+ cells over the course of
months to levels found in healthy subjects [11,16-18].
There remain many unanswered questions regarding
the phenotype, function, and origin of CD3negCD56neg
CD16+ cells in healthy individuals, and how they compare
to the expanded population found during chronic infec-
tious diseases such as HIV-1 infection. We recently dem-
onstrated that including CD7 as an additional positive NK
cell marker is an effective method for studying non-
classical NK cell subsets [23]. Using CD7, we expand our
collective knowledge about the phenotype and function of
CD56negCD16+ cells in healthy and HIV-1-infected sub-
jects. Based upon previous observations that chronic viremia
is associated with an increased frequency of CD56negCD16+
cells, we tested the hypothesis that CD7 would refine the
population of NK cells defined as CD56negCD16+ cells and
provide evidence that CD7+CD56negCD16+ NK cells are ma-
ture NK cells.
Results
CD56negCD16+ cells are a mixed population of myeloid and
NK cells that is expanded during chronic HIV-1 infection
PBMC from HIV-1-negative and HIV-1-infected sub-
jects (Table 1) from the OPTIONS (early infection) and
SCOPE (chronic infection) cohorts were gated on
CD3negCD14negCD19neg cells and the three major NK cell
subsets were assessed: CD56brightCD16neg, CD56+CD16+,
and CD56negCD16+ (Additional file 1). A significant
decrease in the frequency of CD56brightCD16neg and
CD56+CD16+ NK cells with a significant increase inthe frequency of CD56negCD16+ cells was observed in
HIV-1-infected subjects, particularly during chronic HIV-
1 infection (Figure 1A). These results are in agreement
with previous studies describing CD56negCD16+ cells as
highly expanded during chronic HIV-1 (and HCV) infec-
tions [8,12,16,24].
A recent gene expression study of CD56negCD16+
cells, traditional CD56+CD16+ NK cells, and myeloid
cells found that the transcriptome of CD56negCD16+ cells
was more similar to myeloid cells than to traditional
CD56+CD16+ NK cells [25]. Therefore, we hypothesized
that CD56negCD16+ cells are a mixed population of mye-
loid and NK cells that could be distinguished using CD7
[23]. In HIV-1-negative controls, less than 40% of
CD56negCD16+ cells co-express CD7, indicating the
CD56negCD16+ population is not a homogeneous popu-
lation of NK cells (Figure 1B). During early HIV-1 infec-
tion, there is a significant expansion in the frequency of
CD7+CD56negCD16+ NK cells that appears to persist
into chronic HIV-1 infection; however, CD56negCD16+ cells
remain a mixed myeloid and NK cell population (Figure 1B).
In the absence of CD7 gating we did not observe the
expansion of CD56negCD16+ cells during early infection
(Figure 1A). Persistent HIV-1 viremia appears to be import-
ant for the accumulation of CD7+CD56negCD16+ NK cells
[8,12,16,24]. No significant difference was observed in the
frequency of CD7+CD56negCD16+ NK cells in healthy, non-
HIV infected individuals, including both cytomegalovirus-
seropositive and cytomegalovirus-seronegative subjects
(Figure 1C). Taken together, CD56negCD16+ cells are a
mixed population of cells, a subset of which are CD7+ NK
cells that are expanded during persistent HIV-1 viremia.
CD7+CD56negCD16+ and CD7+CD56+CD16+ NK cells are
phenotypically similar in healthy donors; however, HIV-1
infection significantly alters the phenotype of both NK
cell subsets
In the absence of CD7 gating, CD56negCD16+ cells appear
to have no or very low levels of NKp30 and granzyme B ex-
pression. However, when the CD7+CD56negCD16+ NK cells
are gated and compared to mature CD7+CD56+CD16+ NK
cells, little difference between the cell subsets was ob-
served (Additional file 2). As these data are in disagree-
ment with previous reports [12,26], we sought to further
characterize CD7+CD56negCD16+ NK cells compared to
CD7+CD56+CD16+ NK cells in healthy and HIV-1-
infected individuals.
We assessed the expression of Killer cell Immunoglobulin-
like Receptors (KIRs), C-type lectin-like receptors (NKG2A,
NKG2C and CD161), and Natural Cytotoxicity Recep-
tors (NCRs; NKp30, and NKp46), as well as receptors
typically found on myeloid cells (CD33, CD13, and
HLA-DR) in HIV-1-negative donors (Figure 2). No
significant difference was observed in the frequency
Table 1 Early and chronic HIV-1-infected patient viral loads and CD4+ T cell counts
Patient ID Cohort Antiretroviral status Viral load CD4+ T cell count
647 OPTIONS None 73988 594
683 OPTIONS None 95903 480
722 OPTIONS None 124070 522
730 OPTIONS None 2185 594
792 OPTIONS None 128274 281
804 OPTIONS None 4812 800
830 OPTIONS None 14207 850
858 OPTIONS None 56133 466
876 OPTIONS None 149012 343
1049 SCOPE None 336630 218
1070 SCOPE None 365000 331
1091 SCOPE None 59935 288
1208 SCOPE None 17641 1054
1217 SCOPE None 19933 281
1311 SCOPE None 56566 647
1335 SCOPE None 50738 501
1538 SCOPE None 47025 612
1566 SCOPE None 34418 853
1571 SCOPE None 21734 381
1587 SCOPE None 13589 469
1588 SCOPE None 25552 891
1596 SCOPE None 23364 621
1597 SCOPE None 12593 498
1606 SCOPE None 24458 678
1654 SCOPE None 91597 441
1662 SCOPE None 236000 584
1679 SCOPE None 145465 288
4015 SCOPE None 63400 714
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CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells,
although CD7+CD56negCD16+ NK cells had a signifi-
cantly lower frequency of KIR3DS1/DL1-positive NK
cells. The density of KIR2DL1 and KIR2DL3 as mea-
sured by mean fluorescent intensity (MFI) was signifi-
cantly lower on CD7+CD56negCD16+ NK cells, whereas
no significant difference in MFI of KIR3DS1/DL1 was
observed between the NK cell subsets (Figure 2A-C).
With regard to the C-type lectin-like receptors, similar
frequencies of both NK cell subsets expressed NKG2A
and NKG2C. While both NK cell subsets had similar
densities of NKG2C expression, the density of NKG2A
was significantly lower on CD7+CD56negCD16+ NK cells
(Figure 2D-E). No significant differences were observed in
the frequency of NKp30 and NKp46 between the NK cell
subsets (Figure 2G-H). In contrast to previous studies,
NKp30 and NKp46 were expressed at significantly greaterdensities on CD7+CD56negCD16+ NK cells compared
with CD7+CD56+CD16+ NK cells (Figure 2G-H). By in-
cluding all CD7+CD56+ NK cells (i.e. CD56brCD16neg,
CD56brCD16dim, and CD56+CD16+) in the analyses as
was done by Mavilio et al. [12], the MFI of NKp30 and
NKp46 expression remained significantly greater in
CD7+CD56negCD16+ NK cells compared with total
CD7+CD56+ NK cells and CD7+CD56+CD16+ NK cells
(Additional file 3). However, total CD7+CD56+ NK
cells showed a trend (p = 0.070) toward greater NKp46
density compared to CD7+CD56+CD16+ NK cells
(Additional file 3B). No significant differences were ob-
served in the frequency or density of CD161 expression
between CD7+CD56+CD16+ and CD7+CD56negCD16+
NK cells (Figure 2F). A prior study of CD56negCD16+
NK cells indicated a significantly greater expression of
the inhibitory receptor LIR-1 on CD56negCD16+ com-



























   


























   





































































































p < 0.001p < 0.001
p < 0.001
p < 0.001
Figure 1 (See legend on next page.)
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Figure 1 Distribution of NK cell subsets. A, Frequency of classically defined NK cell subsets within the CD3neg CD14neg CD19neg population of
healthy donors ((•) N, n = 63) and early- ((☐) E, n = 9) and chronically- (( ) C, n = 19) HIV-1-infected subjects. B, Frequency of CD3neg CD14neg
CD19neg cells expressing CD7 within the CD56brightCD16neg, CD56+CD16+ and CD56negCD16+ subsets in healthy ((•) N, n = 63) and early- ((☐) E, n
= 9) and chronically- (( ) C, n = 19) HIV-1-infected subjects. C, Frequency of CD56negCD16+ cells within the CD3neg CD14neg CD19neg population
(left axis) and of CD3neg CD14neg CD19neg cells expressing CD7 within the CD56negCD16+ subset (right axis) of CMV-negative (closed circles) and
CMV-positive (open circles) healthy donors. The median and 25th and 75th percentile are indicated on each graph.
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density on CD7+CD56+CD16+ and CD7+CD56negCD16+
NK cells was not significantly different (Figure 2I). Indeed,
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Figure 2 Phenotypic characterization of CD7+CD56+CD16+ and CD7+C
donors. CD3negCD14negCD19neg cells were gated for CD56+ and CD56neg ce
monocyte or DC-like cells. The percentage of CD7+CD56+CD16+ and CD7+CD
expressing each receptor was determined (n = 6). A-I, Expression of NK cell-as
myeloid-associated markers on the different cell subsets. The median and 25tCD56negCD16+ cells was likely due to the contamination
with CD7negCD56negCD16+ myeloid cells that have five-
fold greater LIR-1 density than CD7+ NK cells. Import-
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sociated receptors on the different cell subsets. J-M, Expression of
h and 75th percentile are indicated on each graph.
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quencies of CD7negCD56negCD16+ cells did express CD33,
CD13, and HLA-DR, markers that are classically
expressed by myeloid cells (Figure 2J-L). Recently, Bigley
et al. observed that a subset of CD123+ plasmacytoid den-
dritic cells express CD7 [27]. Although approximately 80%
of the CD7negCD56negCD16+ cells expressed CD123, no
expression of CD123 was observed on CD7+CD56+CD16+
or CD7+CD56negCD16+ NK cells (Figure 2M). These re-
sults are in agreement with Bigley et al. who reported that
CD7+ CD123+ plasmacytoid dendritic cells were CD16-
negative [27]. The phenotypic profile of CD7negCD56-
negCD16+ cells is largely consistent with non-classical
CD14negCD16+ monocytes and a subset of dendritic cells
(DCs) designated slanDCs [28] that fall within the lymph-
oid gate based on light scattering properties.
To determine the impact of HIV-1 infection on the
phenotype of CD7+CD56+CD16+ and CD7+CD56negCD16+
NK cells, KIR, C-type lectin-like receptors, and NCRs were
assessed in 16 chronically HIV-1-infected subjects and 8
healthy controls (Figure 3). HIV-1-infected subjects trended
towards a reduced frequency of NKp30- and NKp46-
positive CD7+CD56+CD16+ NK cells compared to healthy
controls. However, the frequency of NKp30- and NKp46-
expressing CD7+CD56negCD16+ NK cells and the density
of NKp30 and NKp46 expression on CD7+CD56negCD16+
NK cells were significantly lower in HIV-1-infected sub-
jects. Importantly, there were no significant differences in
the frequencies of cells expressing NCRs or the density
of the NCRs between CD7+CD56+CD16+ and CD7+
CD56negCD16+ NK cells in the HIV-1-infected subjects
(Figure 3A and B). Assessment of KIR2DL3 and KIR3DL1/
DS1 did not reveal any significant differences between sub-
sets of NK cells or the HIV-1 infection status of the subject
(Figure 3C and D). A significantly lower frequency of CD7+
CD56negCD16+ NK cells within HIV-1-infected subjects
expressed NKG2A, while the density of NKG2A expression
was significantly greater on CD7+CD56+CD16+ NK cells in
HIV-1-infected subjects (Figure 3E). The frequency of NK
cells and density of the activating receptor NKG2C is ele-
vated in CMV-infected individuals [22,29,30], a co-infection
that is highly prevalent (>98% in the SCOPE cohort [31]) in
HIV-1-infected subjects. To this end, it was not unexpected
to observe that the frequency of NKG2C-bearing cells was
significantly greater on both subsets of NK cells in HIV-1-
infected subjects compared to healthy controls (Figure 3F).
Furthermore, the density of NKG2C expression was signifi-
cantly greater on CD7+CD56+CD16+ NK cells in HIV-1-
infected compared to uninfected individuals. However,
no significant differences were observed between CD7+
CD56+CD16+ and CD7+CD56negCD16+ NK cell subsets
within the HIV-1-infected subjects (Figure 3F). The in-
creased frequency and density of NKG2C+ NK cells in
HIV-1-infected subjects likely represents the higherprevalence of cytomegalovirus infection or reactivation
in these subjects [31]. Taken together these results indi-
cate that HIV-1 infection has a significant impact on
the overall NK cell phenotype. However, with the excep-
tion of NKp30 and NKp46, CD7+CD56negCD16+ NK
cells do not appear to be significantly altered compared
to CD7+CD56+CD16+ NK cells within HIV-1-infected
subjects.
CD7+CD56negCD16+ NK cells are mature NK cells
To determine whether differences in maturation existed
between CD7+CD56negCD16+ and CD7+CD56+CD16+
NK cells, we assessed the expression of CD16, CD57,
Siglec-7, CD62L, and CXCR3. A significantly greater
frequency of CD7+CD56+CD16+ NK cells in HIV-1-
infected subjects expressed CD57 compared to healthy
subjects. Although CD57 expression on CD7+CD56+CD16+
and CD7+CD56negCD16+ NK cells in healthy con-
trols was not significantly different, the frequency
of CD57+CD7+CD56negCD16+ NK cells in HIV-1-
infected subjects was significantly less compared to
CD57+CD7+CD56+CD16+ NK cells (~44% versus ~54%
respectively; Figure 4A). When we separated healthy sub-
jects by CMV serology status, we did not observe a signifi-
cant difference in CD57 expression between the NK cell
subsets (data not shown). CD16 expression increases with
NK cell maturation [21]. We observed that early HIV-1 in-
fection resulted in a significant increase in CD16 expres-
sion on both subsets of NK cells compared to healthy
controls (Figure 4B left half). Because the studies were
performed at different times, we were unable to directly
compare the density of CD16 expression (based on MFI)
in early and chronic HIV-1 infection. However, in contrast
to early infection, CD16 expression did not appear to differ
significantly on CD7+CD56+CD16+ or CD7+CD56negCD16+
NK cell subsets in chronically HIV-1-infected subjects com-
pared to healthy controls (Figure 4B, right half). Recently,
HIV-1 infection was reported to induce a rapid and sus-
tained decrease in Siglec-7 expression on NK cells, which is
associated with impaired function [11]. We observed that
greater than 90% of CD7+CD56+CD16+ NK cells in healthy
donors expressed Siglec-7, whereas approximately 50% of
this NK cell subset expressed Siglec-7 in HIV-1-infected
subjects (Figure 4C). Furthermore, we found that a
lower frequency of CD7+CD56negCD16+ NK cells
expressed Siglec-7 in both healthy controls and HIV-1-
infected subjects, but the loss of Siglec-7 on CD7
+CD56negCD16+ NK cells of HIV-1-infected subjects was
significantly greater (Figure 4C). During NK cell matur-
ation from an immature CD56brightCD16neg to a mature
CD56+CD16+ phenotype, CD62L and CXCR3 expression
are decreased [32-34]. In accordance with a mature
phenotype, CD7+CD56negCD16+ NK cells have similar
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Figure 3 Assessment of CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells in healthy (n = 8) and chronically (n = 16) infected HIV-1
donors. A and B, The frequency and mean fluorescence intensity (MFI) of NKp30 (A), NKp46 (B), KIR2DL3 (C), KIR3DL1/DS1 (D), NKG2A (E) and
NKG2C (F) within CD7+CD56negCD16+ and CD7+CD56+CD16+ NK cells. The median and 25th and 75th percentile are indicated on each graph.
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http://www.retrovirology.com/content/10/1/158cells, which is significantly lower than that expressed by
CD7+CD56brightCD16neg immature NK cells (Figure 4D).
Similarly, less than 5% of both CD7+CD56negCD16+ and
CD7+CD56+CD16+ NK cells express CXCR3 (Figure 4E). By
comparison, approximately 70% of CD7+CD56brightCD16neg
immature NK cells express CXCR3, and HIV-1 infection is
associated with a significantly lower frequency of CXCR3+
CD7+CD56brightCD16neg immature NK cells compared to
healthy controls (Figure 4E). In healthy controls, CXCR3 isexpressed by a significantly lower frequency of CD7+
CD56negCD16+ compared to CD7+CD56+CD16+ NK cells
(Figure 4E). HIV-1 infection was associated with a significant
decrease in the frequency of CXCR3+CD7+CD56+CD16+
NK cells (Figure 4E). Taken together, CD7+CD56negCD16+
and CD7+CD56+CD16+ NK cells are mature NK cell subsets
with at least a fraction being terminally differentiated CD57+
NK cells; however, HIV-1-infection significantly alters the
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Figure 4 Assessment of maturation in NK cell subsets of healthy and HIV-1-infected subjects. A, Frequency of CD7+CD56+CD16+ and
CD7+CD56negCD16+ NK cells expressing CD57 in healthy (n = 62) and early (n = 9) and chronically (n = 19) HIV-1-infected subjects. B, The MFI of
CD16 expression was assessed on CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells in healthy (n = 52) and early (n = 9) HIV-1-infected
subjects (left half), and in healthy (n = 10) and chronically HIV-1-infected subjects (n = 19) (right half). The healthy controls and early HIV-1
subjects were stained and analyzed in a different study with an anti-CD16 antibody conjugated to a different fluorophore than the healthy
controls and chronic HIV-1-infected subjects. Therefore, early and chronic HIV-1-infected subjects cannot be directly compared with regard to
mean fluorescent intensity. C, The frequency of CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells expressing Siglec-7. D-E, The frequency of
CD7+CD56brightCD16neg, CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells expressing D) CD62L and E) CXCR3. The same healthy (n = 10)
and chronic HIV-1-infected subjects (n = 19) used in 4B were used to assess Siglec-7, CD62L and CXCR3. The median and 25th and 75th
percentile are indicated on each graph. ( = healthy; = HIV-1-infected).
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both NK cell subsets
Granzyme B and perforin are important effector molecules
expressed by mature NK cells. In healthy controls, no sta-
tistically significant differences in the frequency of NK cells
expressing granzyme B or the amount of granzyme B in the
NK cell subsets was observed, although a trend toward a
decreased frequency of CD7+CD56negCD16+ NK cells ex-
pressing granzyme B was observed (Figure 5A). In contrast,
the frequency of granzyme B-positive NK cells and the
amount of granzyme B expression were significantly lower
in CD7+CD56negCD16+ NK cells of HIV-1-chronically-in-
fected subjects. No statistically significant differences were
observed between healthy control and HIV-1-chronically-
infected subjects in granzyme B expression within the
CD7+CD56+CD16+ or CD7+CD56negCD16+ NK cell sub-
sets (Figure 5A). A significantly lower amount of perforin
was observed in CD7+CD56negCD16+ NK cells of both
healthy controls and HIV-1-chronically-infected sub-
jects compared with CD7+CD56+CD16+ NK cells
(Figure 5B). The frequency of cells expressing perforinin both CD7+CD56+CD16+ and CD7+CD56negCD16+
NK cell populations was significantly lower in HIV-1-
chronically-infected subjects. Furthermore, the amount of
perforin in CD7+CD56negCD16+ NK cells was significantly
lower compared to CD7+CD56+CD16+ NK cells in HIV-1-
chronically-infected subjects (Figure 5B). Taken together,
significantly reduced granzyme B and perforin expression
in CD7+CD56negCD16+ NK cells of HIV-1-chronically-in-
fected subjects might indicate this NK cell subset has re-
cently degranulated in response to an encounter with
target cells.
CD56negCD16+ NK cells have been described as anergic
and having poor cytokine and cytotoxic function in vitro
[9,10,12]. Indeed, in both healthy controls and HIV-1-
infected subjects, CD7+CD56negCD16+ NK cells expressed
significantly less IFNγ compared to CD7+CD56+CD16+ NK
cells following K562 target cell stimulation (Figure 6A-B).
IL-12 plus IL-18 stimulation did induce IFNγ secretion
from CD7+CD56negCD16+ NK cells in healthy controls, al-
beit less than CD7+CD56+CD16+ NK cells (Figure 6A).
CD7+CD56+CD16+ NK cells from HIV-1-chronically-
AB


































































Figure 5 Perforin and granzyme B expression in CD7+CD56+CD16+
and CD7+CD56negCD16+ NK cells of healthy and chronically
infected HIV-1 subjects. A, Granzyme B expression in healthy donors
and chronically infected HIV-1 subjects. B, Perforin expression in
healthy donors and chronically infected HIV-1 subjects. Healthy
subjects n = 10; chronic HIV-1-infected subjects n = 17. The median
and 25th and 75th percentile are indicated on each graph.
( = healthy; = HIV-1-infected).
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IFNγ-secreting cells in response to either K652 target
cells (p = 0.033) or IL-12 plus IL-18 stimulation (p =
0.011) (Figure 6A-B). CD7+CD56negCD16+ NK cells
from HIV-1-chronically-infected subjects had a signifi-
cantly higher frequency of IFNγ+ cells (p = 0.013) compared
to healthy controls in the unstimulated condition. IFNγ re-
sponses induced by K562 target cells in CD7+CD56negCD16+
NK cells from healthy and HIV-1-chronically-infected sub-
jects were negligible. CD7+CD56negCD16+ NK cells from
HIV-1-chronically-infected subjects failed to produce IFNγ
following cytokine stimulation (Figure 6B). In contrast
to IFNγ responses, no significant differences in the fre-
quencies of CD107a-expressing CD7+CD56+CD16+ and
CD7+CD56negCD16+ NK cells were observed following
K562 target stimulation in healthy controls. Indeed, both
subsets of NK cells were capable of degranulating in re-
sponse to target cell stimulation (Figure 6C). In HIV-1-
chronically-infected subjects, CD7+CD56negCD16+ NK
cells had a significantly higher frequency of CD107a ex-
pression in the unstimulated condition (Figure 6D). In
contrast to their CD7+CD56+CD16+ NK cell counterpart,
CD7+CD56negCD16+ NK cells from HIV-1-chronically-in-
fected subjects did not significantly degranulate following
K562 stimulation (Figure 6C-D). A comparison of CD107a+
cells in CD7+CD56+CD16+ and CD7+CD56negCD16+ NKcells in healthy and HIV-1-chronically-infected subjects did
not result in any statistically significant differences. Taken
together, CD7+CD56negCD16+ NK cells from healthy con-
trols were capable of degranulating following target cell
stimulation. However, HIV-1 infection resulted in a signifi-
cant defect in IFNγ secretion in both NK cell subsets and
in degranulation in CD7+CD56negCD16+ NK cells com-
pared to CD7+CD56+CD16+ NK cells. Interestingly, HIV-1
infection also resulted in a higher frequency of IFNγ secre-
tion and degranulation by CD7+CD56negCD16+ NK cells in
unstimulated conditions.
Increased CD95 expression by CD7+CD56negCD16+
NK cells
Granzyme B and perforin expression are lower in un-
stimulated CD7+CD56negCD16+ NK cells compared to
CD7+CD56+CD16+ NK cells (Figure 5). Furthermore,
unstimulated CD7+CD56negCD16+ NK cells have sig-
nificantly higher basal CD107a expression compared to
CD7+CD56+CD16+ NK cells, particularly in HIV-1-
infected subjects (Figure 6). These data suggest that
CD7+CD56negCD16+ NK cells might represent an acti-
vated subset of NK cells that have recently engaged a
target. Previous studies have shown that resting NK
cells express a basal level of the apoptosis-inducing
receptor CD95 on their cell surface and that upon acti-
vation either through Fc receptor [35] or cytokine
stimulation [36], CD95 is significantly upregulated on
NK cells. Kottilil et al. recently demonstrated that CD95
expression is increased on NK cells in HIV-1-infected sub-
jects predominantly within the CD56+CD16+ NK cell sub-
set [37]. Indeed, we observed that CD95 is significantly
increased on both subsets of NK cells in HIV-1-
chronically-infected subjects compared to healthy con-
trols, but is particularly increased on CD7+CD56negCD16+
NK cells in both healthy controls and HIV-1-chronically-
infected subjects (Figure 7). These data suggest NK cells
are activated during HIV-1 infection and that CD7+
CD56negCD16+ NK cells might represent NK cells that
have recently engaged a target cell.
Discussion
The lineage and biological role of CD3negCD56negCD16+
cells has remained poorly understood. The lack of a truly
NK cell-specific marker and changes in cell phenotype
during HIV-1 infection, as well as the potential overlap
of phenotypic and functional properties of NK cells with
other immune cell subsets, creates difficulties in study-
ing rare and non-classical NK cell subsets. In humans,
NK cells are most commonly identified as CD3negCD56+
lymphocytes with functionally distinct subsets being
further defined by CD16 expression. However, CD16 is
expressed on many other immune cells, including granulo-






















Figure 7 Assessment of NK cell activation in healthy and
chronically HIV-1-infected subjects. CD95 expression on
CD7+CD56negCD16+ compared to CD7+CD56+CD16+ NK cells in
healthy (n = 11) and chronically HIV-1-infected subjects (n = 19).
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Figure 6 Assessment of IFN and CD107a expression by CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells following in vitro
stimulation. A-B IFNγ expression was compared between CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells in (A) healthy and (B) chronic
HIV-1-infected donors following incubation in media alone, IL-12 plus IL-18, or K562 target cells. C-D, CD107a expression was compared between
CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells in (C) healthy and (D) chronic HIV-1-infected donors following incubation in media alone or
K562 target cells. A total of 10 healthy and 19 chronic HIV-1-infected donors were assessed. A minimum of 200 cells and 70 cells were analyzed
for IFNγ and CD107 expression in CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells, respectively, of healthy donors. A minimum of 550 cells
and 100 cells were analyzed for IFNγ and CD107 expression in CD7+CD56+CD16+ and CD7+CD56negCD16+ NK cells, respectively, of HIV-1-infected
donors. The median and 25th and 75th percentile are indicated on each graph. ( = CD7+CD56+CD16+ NK cells; = CD7+CD56negCD16+
NK cells).
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however, they do express CD13, CD33, HLA-DR, and high
surface expression of CD16, which is the phenotype we ob-
served on the CD7negCD56neg population of cells. There-
fore, caution is needed in interpreting the frequencies and
functions of CD56neg NK cells. Here, we built upon our
previous work using CD7 as an informative marker of NK
cells and demonstrated that CD3negCD56negCD16+ cells
are a mixed population of CD7+ NK cells and CD7neg mye-
loid cells present in both healthy and HIV-1-infected sub-
jects. Previously published microarray analyses support this
observation as the CD3negCD56negCD16+ population ex-
hibited a transcriptome more closely related to myeloid
cells than traditional CD3negCD56+CD16+ NK cells [25].
Our study has provided a more detailed understanding of
the phenotype, function, and possible origin during chronic
HIV-1 infection, of CD7+CD56negCD16+ NK cells in
healthy and HIV-1-infected subjects.
Little is known regarding the phenotype and function of
CD56negCD16+ cells in healthy subjects and whether these
cells are similar to those observed in chronic viral infec-
tions. In HIV-1-negative subjects, we observed minor al-
terations in KIR, NCR, or C-type lectin-like receptors
between the two NK cell subsets. In contrast to a previous
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CD56negCD16+ cells in healthy donors [38], we observed
that CD7+CD56negCD16+ NK cells actually had increased
NKp30 expression. Functionally, CD7+CD56negCD16+ NK
cells had impaired cytokine responses following K562 tar-
get cell or IL-12 plus IL-18 stimulation; however, they
degranulated (as measured by CD107a-expression) similar
to CD7+CD56+CD16+ NK cells following K562 target cell
stimulation. By removing CD7neg non-NK cells, we dem-
onstrated that CD7+CD56negCD16+ NK cells do not have
as significantly altered of a phenotype as previously shown.
While our results confirm that CD56neg NK cells do exist
in healthy donors, using CD7 provided for a precise deter-
mination of the frequency of CD56neg NK cells present in
the blood of healthy donors and allowed for analyses of
their phenotype and functional characteristics.
Numerous studies have found decreases in both fre-
quency and absolute numbers of NK cells defined as
CD3negCD56+ with a concomitant increase in a population
of CD3negCD56negCD16+ cells in HIV-1 infection [6-8].
Our results confirm the expansion of a CD56neg NK cell
population; however, this population is not homogenous
(<70% were CD7+CD56negCD16+ NK cells). KIR expres-
sion was not significantly altered on either CD7+CD56+ or
CD7+CD56neg NK cells during HIV-1 infection compared
to healthy donors. While HIV-1 infection was not associ-
ated with significant alterations in the frequency of cells
expressing NKp30 or NKp46 in the CD7+CD56+ NK cell
population, we did observe significant reductions in dens-
ity of these receptors on CD7+CD56neg NK cells. During
HIV-1 infection, CD7+CD56neg NK cells appeared to be
mature; however, there were fewer CD57+ terminally
differentiated CD7+CD56neg compared to CD7+CD56+
NK cells. We recently demonstrated that CD57 is a
marker of terminally differentiated NK cells [21], and
that CD57+NKG2Chi NK cells take weeks to develop
in vivo following cytomegalovirus infection [22]. One pos-
sible explanation for the expansion of this CD7+CD56neg
NK cell subset is that during HIV-1 infection, the already
rapid turnover of NK cells [20] is further accelerated, pre-
venting this subset of NK cells from terminally differenti-
ating and gaining CD57 expression. Furthermore, our
observation that CD7+CD56neg NK cells express more of
the apoptosis-inducing receptor CD95 further suggests
these cells might undergo apoptosis prior to becoming ter-
minally differentiated.
An alternative hypothesis is that the expanded population
of CD7+CD56negCD16+ NK cells during HIV-1 infection
represents mature NK cells that arise at least in part when
CD7+CD56+CD16+ NK cells engage target cells. NK cells
are capable of killing multiple target cells and this results in
a reduced, but never complete, loss of perforin and gran-
zyme B [39]. Here, decreased granzyme B and perforin ex-
pression and increased expression of CD107a in the absenceof ex vivo stimulation within the CD7+CD56negCD16+ NK
cells, particularly of HIV-1-infected subjects, suggests that
CD7+CD56negCD16+ NK cells may have recently engaged
target cells in vivo. This is further supported by the in-
creased expression of CD95 on CD7+CD56negCD16+ NK
cells, indicating these cells are more activated than their
CD7+CD56+CD16+ NK cell counterparts.
Importantly, the frequency of CD7+CD56negCD16+ NK
cells decreases in vivo during antiretroviral treatment
[9,11,40] and in vitro with the addition of IL-2 [12]. In-
deed, IL-2 has been shown to help recover perforin and
granzyme B expression in NK cells that have killed target
cells [39]. Furthermore, one study suggests that IL-2 may
be beneficial in restoring CD56+CD16+ NK cells as they
observed an increase in CD56+CD16+ NK cells and a re-
duction in CD56negCD16+ NK cells in vivo [41]. The
in vivo efficacy of IL-2 plus antiretroviral therapy requires
further exploration. Another interesting approach is the
combinatorial use of statins, particularly hydrophilic sta-
tins, with cytokine therapies. Statins are known to protect
against oxidative stress [42] and hydrophilic statins do not
inhibit NK cell cytotoxicity [43]. Such therapies may afford
an individual increased control of viral replication prior to
initiating antiretroviral therapy and provide increased clear-
ance of viral reservoirs during antiretroviral therapy or in
the event of drug resistance. Future studies investigating
the effects of cytokine and statin therapies in chronic in-
flammatory diseases are needed to determine whether they
help maintain a healthy NK cell repertoire.
Conclusion
Taken together, CD56negCD16+ NK cells are a mixed popula-
tion of CD7+ NK cells and CD7neg myeloid cells present at a
low frequency in healthy donors irrespective of CMV ser-
ology status and expanded in HIV-1 viremic subjects. Our
results indicate CD7+CD56negCD16+ NK cells are activated,
mature NK cells that may have recently engaged target cells.
Further in vivo studies are needed to evaluate treatments for
maintaining NK cell functionality in HIV-1 viremic subjects
through the use of cytokine and statin therapies.
Methods
Human subjects
Density gradient centrifugation n over Ficoll-Paque (GE
Healthcare) was used to obtain PBMC from leukocyte con-
centrates of healthy volunteers (Stanford Blood Center).
Additionally, PBMC were obtained from participants in
two San Francisco-based HIV-1-infected cohorts, OP-
TIONS that recruits subjects during early HIV-1 infection
[44] and SCOPE that recruits subjects during chronic HIV-
1 infection [45]. Table 1 summarizes the subjects used
from each HIV-1 cohort and their respective CD4+ T
cell counts and viral loads. All persons gave informed
consent to participate in this study, and the University
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Research approved this study.
Phenotypic and functional characterization of cell subsets
With the exception of the following antibodies, all
fluorophore-labeled antibodies used for phenotypic analysis
have been previously described [23]: phycoerythrin (PE)-
conjugated anti-Siglec 7 (BioLegend) and PE-conjugated
anti-LIR-1 (Beckman Coulter). All stains were performed in
the presence of 100 μg/mL human IgG to block Fc recep-
tors. No significant differences in isotype-matched control
Ig staining were observed between CD7+CD56+CD16+ NK
cells and CD7+CD56negCD16+ NK cells. Cells were ana-
lyzed by flow cytometry with a four-laser LSR-II instru-
ment (BD Biosciences, San Jose, CA) as previously
described [23] and data analyses were carried out using
FlowJo flow cytometric analysis software version 9.3.1
(Tree Star, Ashland, OR).
NK cell stimulation and intracellular cytokine staining
NK cell stimulation with K562 target cells or IL-12 plus
IL-18, as well as intracellular IFNγ staining, was per-
formed as previously described [23].
Statistical analysis
Statistical analyses were performed with GraphPad Prism
software (GraphPad Software). The nonparametric Mann–
Whitney U test was used to compare between-group distri-
butions with a significance threshold set at p < 0.05.
Additional files
Additional file 1: Gating strategy to identify NK cell subsets in a
representative healthy donor. Single, live cells were gated on
lymphocytes based on forward and side scatter parameters. CD3neg,
CD14neg, and CD19neg cells were gated and used to identify classically
defined NK cells using CD56 and CD16 expression. To eliminate any
potential contaminating myeloid cells, CD7 was assessed on each subset
of classically defined NK cells (CD56brCD16neg (green), CD56dimCD16+
(red) and CD56negCD16+ (teal)). All three subsets contained CD7neg cells;
however, the CD56negCD16+ subset contained the highest proportion of
CD7neg non-NK cells. Overlaying the CD7neg non-NK cells onto the CD7+
NK cells indicates the high overlap within the subsets and the usefulness
of CD7 as an additional marker of NK cells.
Additional file 2: CD7 gating allows precise identification of NK
cells. CD56+CD16+ (red) or CD56negCD16+ (blue) cell subsets were
assessed for NKp30 or granzyme B expression without gating on CD7+
cells (left panels) or after gating on CD7+ NK cell subsets (right panels).
Additional file 3: Comparison of NK cell gating strategies on NKp30
and NKp46 expression. (A) NKp30 and (B) NKp46 expression were
assessed on NK cells defined in three ways; (1) CD7+CD56+CD16+ NK
cells, (2) total CD7+CD56+ NK cells inclusive of CD56brightCD16neg,
CD56dimCD16neg and CD56dimCD16pos NK cells and (3) CD7+
CD56negCD16+ NK cells.
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